Specialising in the field of chemistry, particularly medical devices, fibres, fabrics, personal care and cosmetics, Inge has over 20 years of experience in the patent profession both in-house and in private practice. She deals with all IP related topics, in particular drafting and prosecuting patent applications, EPO opposition and appeal proceedings, opinions on freedom-to-operate and validity as well as IP strategy and portfolio management.
Inge has extensive experience dealing with freedom-to-operate, infringement and validity opinions which she partly obtained during the 11 years she worked in-house for a leading specialty chemical company in Germany. She has a broad range of expertise handling oppositions and appeals at the EPO as well as drafting and prosecuting patent applications worldwide.
In addition, she has managed global patent portfolios both in private practice and in-house providing strategic advice to patent professionals, marketing and application technology leaders. She also advises on the German law for employee’s inventions.
Inge graduated at RWTH Aachen University in Germany and obtained a PhD in Chemistry at the DWI Aachen while working on projects for the German Federation of Industrial Research Associations (AIF).
After two years of running the search department of a leading personal healthcare company, Inge joined a specialty chemical company where she qualified as a European Patent Attorney. She moved to Scotland in 2012 to work in private practice, before joining the Edinburgh office of HGF in January 2016.
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
HGF in Europe and Knobbe Martens in the US are holding a joint webinar on 9th June. In this webinar we will explore considerations for implementing an effective strategy to …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.